你即將離開本站

並前往https://www.businesswire.com/news/home/20211120005130/en/Exelixis-Announces-Detailed-Results-from-Phase-3-COSMIC-312-Pivotal-Trial-of-Cabozantinib-in-Combination-with-an-Immune-Checkpoint-Inhibitor-in-Patients-with-Previously-Untreated-Advanced-Liver-Cancer-at-ESMO-Asia-Virtual-Oncology-Week-2021

Exelixis Announces Detailed Results from Phase 3 COSMIC ...

... with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer at ESMO Asia Virtual Oncology Week 2021.

確定！ 回上一頁

查詢 「ESMO Asia」的人也找了：

  1. esmo asia 2022
    2.
  2. esmo io 2022
    3.
  3. ESMO Asia 2021
    4.
  4. esmo asia 2022 abstract deadline
    5.
  5. ESMO 2021
    6.
  6. esmo asia abstract deadline
    7.
  7. WCLC 2022
    8.
  8. esmo 2022
    9.